Related Experiment Video
Updated: May 14, 2026

Cell-based Assay Protocol for the Prognostic Prediction of Idiopathic Scoliosis Using Cellular Dielectric Spectroscopy
Published on: October 16, 2013
Long-Term Cost-Effectiveness of Case Finding and Mass Screening for Celiac Disease in Children
Jan Heijdra Suasnabar1, Caroline R Meijer2, Lucy Smit3
1Department of Biomedical Data Science, Leiden University Medical Centre, Leiden, the Netherlands.
Insights
Early detection of celiac disease (CD) in children through point-of-care testing is cost-effective. Both mass screening and case finding strategies improve health outcomes compared to current care, with mass screening potentially being optimal.
Area of Science:
- Pediatric autoimmune diseases
- Public health strategies
- Health economics
Background:
- Celiac disease (CD) is a common autoimmune disorder often diagnosed late.
- Point-of-care tests for CD antibodies could facilitate early detection in primary care.
- Evidence on the cost-effectiveness of early CD detection strategies is limited.
Purpose of the Study:
- To estimate the long-term cost-effectiveness of active case finding and mass screening for CD in children compared to current clinical detection methods in the Netherlands.
Main Methods:
- A decision tree and Markov model simulated a cohort of 3-year-old children.
- The model assessed long-term costs (societal perspective) and quality-adjusted life-years (QALYs).
- Data were sourced from the GLUTENSCREEN project, Dutch Celiac Society, and published literature.
Main Results:
- Mass screening yielded 7.46 more QALYs at an additional cost of €28,635 (ICER: €3841/QALY).
- Case finding yielded 4.33 more QALYs at an additional cost of €15,585 (ICER: €3603/QALY).
- Both strategies were highly cost-effective at a willingness to pay of €20,000/QALY; mass screening is likely optimal.
Conclusions:
- Early identification of CD in children via point-of-care testing improves health outcomes and is cost-effective long-term.
- Implementation of these strategies in Dutch healthcare is recommended if feasible and acceptable.
- Earlier diagnosis through screening or case finding offers significant benefits over current care.
Background & Aims:
Celiac disease (CD) is a common yet underdiagnosed autoimmune disease with substantial long-term consequences. High-accuracy point-of-care tests for CD antibodies conducted at youth primary health care centers may enable earlier identification of CD, but evidence about the cost-effectiveness of such strategies is lacking. We estimated the long-term cost-effectiveness of active case finding and mass screening compared with clinical detection in the Netherlands.
Methods:
A decision tree and Markov model were used to simulate a cohort of 3-year-old children with CD according to each strategy, taking into account their impact on long-term costs (from a societal perspective) and quality-adjusted life-years (QALYs). Model parameters incorporated data from the GLUTENSCREEN project, the Dutch Celiac Society, the Dutch Pediatric Surveillance Unit, and published sources. The primary outcome was the incremental cost-effectiveness ratio (ICER) between strategies.
Results:
Mass screening produced 7.46 more QALYs and was €28,635 more costly compared with current care (ICER: €3841 per QALY), and case finding produced 4.33 more QALYs and was €15,585 more costly compared with current care (ICER: €3603 per QALY). At a willingness to pay of €20,000 per QALY, both strategies were highly cost-effective compared with current care. Scenario analyses indicated that mass screening is likely the optimal strategy, unless no benefit in detecting asymptomatic cases is assumed.
Conclusions:
An earlier identification of CD through screening or case finding in children using a point-of-care tests leads to improved health outcomes and is cost-effective in the long-term compared with current care. If the feasibility and acceptability of the proposed strategies are successful, implementation in Dutch regular care is needed.
More Related Videos
Related Concept Videos
Longitudinal Research
Preventive Healthcare Services
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health condition at a...
Longitudinal Studies
Investigation of Disease Outbreaks

